advanceCOR GmbH

Biotechnology

  • Short facts

    • Research & Development
  • Year founded 2012
  • 25 Employees (site)
  • Turnover: not available

Products/services: advanceCOR is a clinical drug developing company, focusing on novel therapeutics and diagnostics for the treatment of heart and vascular diseases. The focus is on the personalized treatment of cardiovascular diseases with large unmet medical need. We provide truly innovative treatments with a companion diagnostic. advanceCOR´s activities and experiences comprise all steps from research to clinical drug development and commercialization. One project (Revacept) is in the phase II study at different university hospitals. One project is in the preclinical phase (COR-2) and others in the scientific test stage (COR-3). advanceCOR carries out GLP-certified measurements of substances in buffer and serum for preclinical and clinical drug development. advanceCOR has also received a good manufacturing practice (GMP) certificate to carry out analytical studies, and has been granted the status of a drug manufacturer. advanceCOR is a clinical drug developing company, focusing on novel therapeutics and diagnostics for the treatment of heart and vascular diseases. The focus is on the personalized treatment of cardiovascular diseases with large unmet medical need. We provide truly innovative treatments with a companion diagnostic. advanceCOR´s activities and experiences comprise all steps from research to clinical drug development and commercialization. One project (Revacept) is in the phase II study at different university hospitals. One project is in the preclinical phase (COR-2) and others in the scientific test stage (COR-3). ... read more 

Basic data

Company

advanceCOR GmbH

Street

Fraunhoferstr. 9a

PC / City

82152 Planegg

County

Upper Bavaria

Phone

+49 89 2000204-10

Fax

+49 89 2000204-20

Language skills

English, German

Contact person

Management: Prof. Dr. Götz Münch (Mr.)
Management: Prof. Dr. Martin Ungerer (Mr.)

Profile/competences

Core competencies

Product development
Revacept
GPVI inhibiting antibodies
COR-2

Key sectors / sub-sectors

  • Biotechnology: Therapeutic drug development

NACE industries

  • Scientific research and development 72
  • Research and experimental development on natural sciences and engineering 72.1
  • Research and experimental development on biotechnology 72.11

Certifications / awards

not available

Sales markets - target industries

not available

Sales markets - target countries

not available

Cooperation offers

not available